Pfizer vaccine, “effective in 5-11 year olds at lower doses”

Pfizer and BioNTech today announced the results of a phase 2/3 study showing for their Covid vaccine “a favorable safety profile and a robust response” in terms of neutralizing antibodies in children aged 5 to 11. , using a two-dose regimen of 10 micrograms (µg) 21 days apart. This is a lower dose than that (30 µg) used for people aged 12 years and over. The antibody responses in the participants who were given these quantities “were comparable to those recorded in a previous Pfizer-BioNTech study in people aged 16-25 years immunized with doses of 30 µg,” the two companies explain in a note. . “The 10 µg dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children aged 5 to 11 years.”